Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relaps… (NCT07643805) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL
China46 participantsStarted 2026-06-01
Plain-language summary
Single-Arm Clinical Study of Zeprumetostat in Combination with Glofitamab + GemOx in Patients with Relapsed/ Refractory DLBCL
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥ 18 years, male or female;
. Histologically confirmed diffuse large B-cell lymphoma (DLBCL);
. Relapsed/refractory (R/R) disease；
. At least one prior line of therapy containing rituximab;
. Subjects must have at least one measurable lesion;
. ECOG PS 0-2;
. Life expectancy ≥ 3 months;
. Adequate organ and bone marrow function, without severe hematopoietic abnormalities or cardiac, pulmonary, hepatic, renal, thyroid dysfunction, or immunodeficiencies;
Exclusion criteria
. Patient is a candidate for hematopoietic stem cell transplantation.
. Primary or secondary central nervous system (CNS) lymphoma or history of CNS lymphoma.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Complete response rate, CRR
Timeframe: From first dose to end of treatment (assessed up to 12 months)
Trial details
NCT IDNCT07643805
SponsorThe First Affiliated Hospital with Nanjing Medical University
. History of severe hypersensitivity or anaphylactic reaction to humanized or murine monoclonal antibodies.
. Prior treatment with an EZH2 inhibitor, and/or an anti-CD20 and CD3 bispecific antibody, and/or GemOx (gemcitabine and oxaliplatin).
. History of other malignancies within the past 2 years requiring systemic therapy.
. Receipt of systemic anti-neoplastic therapy, including chemotherapy, immunotherapy, biologic therapy, etc., within 14 days prior to the start of study treatment.
. Major surgery (excluding diagnostic procedures) within 28 days prior to the start of study treatment.